Mutation
Introduction
The incidence of resistance to isoniazid and rifampicin (multidrug-resistant tuberculosis; MDR-TB), is a worldwide problem [1, 2] .
Fluoroquinolones are the first new antimycobacterial drugs to be available since the discovery of rifampin against Mycobacterium tuberculosis and are part of the treatment recommended for MDR-TB. The increasing use of quinolones in the community can lead to decreased quinolone susceptibility in M. tuberculosis. This raises interest in the mechanisms of resistance in this organism [2] [3] [4] [5] .
Spontaneous mutations in chromosomal genes are the main cause of drug resistance in M. tuberculosis. They may have produced the selection of resistant strains during suboptimal drug therapy [6] .
The most important mechanism of fluoroquinolone resistance in M. tuberculosis is mutations in the fluoroquinoloneresistance determining region of the gyrA gene. To determine the mutations in the fluoroquinolone-resistance determining region a marker could be used for the detection of fluoroquinolone resistance in M. tuberculosis [7] .
The MDR form is produced by sequential accumulation of mutations in different genes involved in the resistance to individual drugs due to inappropriate treatment [4, 5] .
In Iran, the incidence of TB cases (all forms) in 2008-2009 was 23 in 100,000 individuals and mortality was three deaths/100,000 population/y [3] [4] [5] .
The natural drug resistance of M. tuberculosis is an important obstacle for the treatment and control of TB. This resistance has traditionally been attributed to the unusual multilayer cell envelope and active multidrug efflux pumps [5] [6] [7] [8] .
Methods for the detection of drug resistance include both phenotypic and genotypic methods. Phenotypic methods might be closer to implementation on a routine basis in mycobacteriology laboratories. Genotypic methods have the advantage of a rapid test, no need for growth of bacterium, the possibility of direct application in clinical samples, and the feasibility of automation. However, to date, not all molecular mechanisms of drug resistance are known very well [6] .
The aim of this study was to assess the susceptibility of quinolones among M. tuberculosis strains and to survey the putative mutations associated with quinolone resistance in the a-subunit of the gyrA gene in some clinical strains of M. tuberculosis isolated from Iranian and Belarusian patients.
Materials and methods

Patients
One hundred and forty patients from Belarus and 44 patients from Iran were entered in the study as per World Health Organization recommendation methods [2, 5, 8] .
M. tuberculosis isolates
Patient samples were cultured on Lö wenstein-Jensen medium (Merck KGaA 64271, Heidelberg, Germany). Sputum collection and inoculation was carried out in the National Reference Laboratory of the Research Institute for Pulmonology and Phthisiology of Belarus and the National Research Institute of Tuberculosis and Long Disease of Iran.
M. tuberculosis H37Rv was included as a control strain in the drug-susceptibility testing and molecular experiments.
Drug susceptibility testing
Susceptibility testing was accomplished using the absolute concentration method on Lö wenstein-Jensen medium. A microbial suspension containing 5 Â 10 8 organisms/mL was prepared as per McFarland turbidity and was diluted to 1:10, and 0.2 mL was then added to the Lö wenstein-Jensen medium. The culture tubes were incubated at 37°C, and growth was achieved after 3-4 weeks of incubation. An isolate was considered resistant when bacterial growth occurred in the presence of a concentration of 2 lg/mL ofloxacin by the BACTEC system (MGIT 960; Becton Dickinson Microbiology Systems, Sparks, Maryland, USA) in a Level III laboratory.
Bacterial genomic DNA isolation
Bacterial genomic DNA was extracted using the Genomic DNA Purification Kit (Genomic DNA Purification Kit (#K0512 Fermentas, Vilnius, Lithuania)) according to the manufacturer's instructions. Furthermore, Chelex-100 method was used briefly by heating of two colonies dissolved in Tris-acetate-EDTA (TAE) buffer in 5% the Chelex 100 Resin (Bio-Rad, Berkeley, CA, USA; part 143-.3832, 100-200 mesh Chelex, sodium form) for 45 min in 95°C followed by centrifugation for 15 min three times at 21952g. This is because Chelex 100 would interfere with the polymerase chain reaction (PCR) reaction and needs to be totally removed [9] .
PCR amplification of genome fragments
Amplification of genome fragments of the gyrA gene of clinical isolates of M. tuberculosis was accomplished as following for PCR and the subsequent sequencing method. Detection of the 194-bp DNA fragment of the gyrA gene was performed by PCR amplification with oligonucleotide primers gyrA-F: 5 0 -CGATTCCGGCTTCCGCCCGG-3 0 and gyrA-R: 5 0 CCGGTGGGTCA TTGCCTGGCG-3 0 . The primers produce a product of 194 bp at an annealing temperature of 68°C [10] .
The PCR reaction was performed in a volume of 50 lL of a reaction mixture containing 10-lL purified DNA, 5-lL 10 Â Taq Buffer (containing [NH 4 ] 2 SO 4 and 20 mM MgCl 2 ), 1 lL of seoxynucleotides 10 mM each (Fermentas R0192 Fermentas, Vilnius, Lithuania), 1 U Taq polymerase, and 25 pmols of each primer. PCR cycles were as follows: one cycle at 95°C for 4 min, 40 cycles started at 94°C for 40 s, 68°C for 1 min, 72°C
for 20 s, with a final cycle at 72°C for 10 min. Gel electrophoresis method was used for the detection of gene bands on agarose gel. A 10-lL aliquot of the PCR product was used for electrophoresis reaction for 1.5 h on 1.5% agarose gel in 1Â TAE buffer at 80 V. A DNA marker (50-bp Fermentas) was used for size determination of the bands. The agarose gel was prepared by TAE buffer with the addition of ethidium bromide.
Amplified 194-bp bands of the gyrA gene were extracted from the gel by a kit (Fermentas, K0513, Vilnius, Lithuania) according to manufacturer's instruction. The concentration of purified DNA was measured by a Nucleic Acid analyzer (DU 730, Biochrom WPA Biowave DNA Life Science UV/visible spectrophotometer).
Principal genotypic groups among the isolates were determined as mentioned in a previous study [11] .
DNA sequencing
DNA fragments of 194 bp from the gyrA gene were amplified in a Rotor-Gene (RG-3000; Corbett Research Inc., VA, USA) and Personal Thermo Cycler MJ MiNi (Bio-Rad) with a Thermo-Sequenase Cy5 Dye Terminator Sequencing Kit (GE Healthcare, Buckinghamshire, UK; 27-2682-01). Sequencing was performed using a DNA sequencer by Applied Biosystems (3130; Applied Biosystems, Foster City, CA, USA) apparatus. 
Results
Patient's characteristics
Results of drug susceptibility testing
From the 184 clinical isolates of M. tuberculosis from both countries, 42 isolates consisting of 20 strains from Iran and 22 isolates from Belarus were selected. All of them proved resistant to 2-lg/mL ofloxacin (Apotex Corp. Canada) by drug susceptibility testing. Furthermore, eight MDR (susceptible to ofloxacin) and two pan-susceptible strains were randomly selected and used in this work.
DNA purification and PCR
DNA extraction by Chelex 100 was the best approach for purification and maintenance of DNA over a long period of time (over 5 years).
PCR method using primers for amplification of 194-bp amplicon can further detect all resistant and susceptible isolates which were identified with conventional methods.
Sequencing of the QRDR part of gyrA gene in resistant clinical isolates of M. tuberculosis
Forty-two clinical isolates were studied for the molecular basis of drug resistance to fluoroquinolone drugs. The study was based on the detection of the nucleotide sequence of QRDRs of the gene encoding the a-subunit of DNA gyrase (gyrA) by a sequencing method.
A frequency of amino acid and nucleotide substitutions in codons 90, 91, and 94 gene gyrA was determined in resistant isolates by sequencing (Table 1, Fig. 1 ).
It was revealed that a mutation in codon 94 (GAC to AAC, GGC, TAC, GCC, or ACT) was a frequent one as it was observed in 24 (57%) of the 42 resistant isolates. Eighteen (43%) of the investigated resistant isolates contained mutations in codon 90 (GCG GTG) and five isolates had two simultaneous mutations in codons 90 (GCG GTG) and 94 (GAC CAC) (Tables 1 and 2, Fig. 2 ). There was no difference between mutations in resistant isolates of the two countries (P < .001). A mutation in codon 95 was identified in all MDR (susceptible) and resistant Iranian and Belarusian isolates, but was not observed among the pan-susceptible isolates. Given that the MDRisolates were not resistant to fluoroquinolones, this has proved that a mutation in this codon is not related to fluoroquinolone resistance (Fig. 2) .
Our findings confirmed that 26% of isolates belonged to Principle Genetic Group (PGG) 1. It was assumed that PGG1 being evolutionarily older than other groups and the classification referred to strain Beijing in a subgroup of Genetic Group 1.
Discussion
In this study, gyrA mutations were predominantly found to occur in codons 90, 91, and 94, corroborating the findings of the other studies [12, 13] which is in agreement with previous studies showing that fluoroquinolone resistance of M. tuberculosis is mostly attributed to the mutations of the gyrA gene [12, 14, 15] .
Our results demonstrate the relationship between nucleotide sequences in gyrA and the phenotypic susceptibility to ofloxacin in 42 M. tuberculosis clinical isolates.
Five isolates showed double mutations in codons 90 and 94. In the present study, we reported two patterns of double mutations in five isolates: three with A90V (GCG ? GTG) and D94A (GAC ? AAC) and two with A90V (GCG ? ACG) and D94A (GAC ? AAC). Previous reports on double mutations mainly focused on one kind of codon-90 mutation [13, 16, 17] . However, the presence of different populations either as variants of the same isolate or as a mixture of two genetically independent isolates was shown in this study. It needs to be mentioned that the double mutants, D94G/D94N, must be the result of mixed populations as they cannot be present in the same codon; however, this situation was not detected in the present study.
In the ofloxacin-resistant M. tuberculosis clinical isolates, 35 of 42 (83.3%) had mutations in the QRDR of the gyrA gene, and the other had no mutations with a wild-type gyrA sequence-a finding consistent with those previously reporting averages of 80-85% [12, 15, 19] . Other resistance mechanisms, such as mutations in areas of gyrA outside of the QRDR, decreased cell-wall permeability to the drug, and efflux pumps may be accounting for the fluoroquinolone resistance in fluoroquinolone-resistant isolates without gyrA mutations.
The frequency of the gyrA gene total mutation in the present study was similar to those of Cui et al. [12] (89.5%) and Mokrousov et al. [19] (83%) but higher than those of the Yin and Yu [15] (73.3%) and Haung et al. [18] (50%) reports.
Furthermore, in these ofloxacin-resistant isolates, 25 of 42 (59.5%) had mutations in the codon 94 of the gyrA gene, and the others had mutations in 90 and 91, which is consistent with what has been previously reported on fluoroquinolone resistance [12] [13] [14] [15] [16] [17] .
The mechanism of fluoroquinolone resistance in M. tuberculosis occurs by mutations in DNA gyrase. For this reason, it is important to detect all mutations in DNA gyrase genes of M. tuberculosis and determine the role of these mutations in fluoroquinolone resistance.
Determination of drug resistance by traditional methods requires 5-12 weeks because M. tuberculosis is a slowgrowing bacterium. Rapid molecular methods facilitate the diagnosis of resistance, including MDR-TB and extensively drug-resistant TB, which can occur faster than with conventional susceptibility testing.
The most widely used rapid molecular method to detect fluoroquinolone resistance was PCR and DNA sequencing. More rapid testing methods included multiplex allele-specific PCR, PCR single-strand conformation polymorphism/multiplex PCR amplimer conformation, pyrosequencing, denaturing high performance liquid chromatography, real-time PCR (locked nucleic acid-PCR), and GenoType MTBDR line probe [12, [15] [16] [17] [18] [19] .
The possible roles of the mutations in QRDR and their relationships with fluoroquinolone resistance were studied. Our results showed that the polymorphism at codon 95, encoding either serine or threonine, did not have a significant impact on fluoroquinolone susceptibility.
Previously reported mutations involving codon 88 were not found in our strains. Double mutations in gyrA, while not uncommon in the isolates obtained through antimicrobial selection in other studies, were detected in our study [6, [12] [13] [14] [15] .
The results of nucleotide sequencing of gyrA QRDRs were analyzed for 42 isolates resistant to ofloxacin (20 isolates from Iran and 22 from Belarus). Studying the molecular basis of resistance in drug-resistant clinical isolates of M. tuberculosis to fluoroquinolone drugs has identified mutations in QRDR of the gyrA gene from isolates of M. tuberculosis.
Genotyping allows the identification and characteristic descriptions of isolates circulating in different regions, groups, and ways to track the spread of resistant and more virulent variants. Development of drug resistance is directly Type of resistance   H 264  ------3  Susceptible  H 232  ------1  Susceptible  11T  -----Thr+  2  MDR  2T - dependent on the frequency and duration of proper drug use for the treatment of TB. Ultimately, the selection of mutant isolates and their rapid accumulation in the population, determines the spread of resistance to drugs. Other than mutations affecting gyrA and fluoroquinolone resistance, there are other mechanisms including efflux pumps, decreased cell-wall permeability to drugs, and perhaps drug inactivation. Fluoroquinolone resistance can rarely be associated with gyrB mutations and may be a probable efflux mechanism. There is a natural polymorphism in codon 95 in the sequences of gyrA that is not associated with resistance that occurs in both fluoroquinolone-sensitive and fluoroquinolone-resistant bacteria. Fluoroquinolone drugs are broad-spectrum antibiotics for the treatment of undiagnosed infections. For this reason there is concern about the levels of fluoroquinolone-resistant TB in regions with high drug resistance rates.
In the absence of antibiotics, the resistant forms will be replaced by more viable susceptible mycobacteria. However, in patients receiving anti-TB drugs, resistant bacteria often survive. Thus, the presence of mutations does not impair viability, as well as compensatory evolution suggests that antibiotic-resistant bacteria will persist in the population, even if it applied the policy of rational use of antimicrobials.
Based on the above, we conclude that the determination of the amino acid sequence regions, which determine resistance to quinolone (QRDRs) in the subunit-a of the DNA gyrase gene could be used as a molecular marker of mycobacterial resistance to fluoroquinolones.
Mycobacteria do not have an outer membrane comparable to that of gram-negative bacteria, but the cell wall contains a very complex lipid bilayer on the surface, which probably acts like an outer membrane and limits the penetration of many antimicrobial agents. Fluoroquinolones are relatively lipophilic drugs, and their penetration appears to be mainly through the lipid domains of mycobacterial cell walls.
Our findings confirm that 26% of isolates belonged to PGG1. It is assumed that PGG1 is evolutionarily older than other groups and the classification referred to the strain Beijing from a subgroup of Genetic Group 1. It was found that these strains caused outbreaks of infection.
Conclusion
In conclusion, a relationship between phenotypic resistance to fluoroquinolones and mutations in QRDRs were detected among M. tuberculosis clinical isolates of Belarus and Iran. However, frequencies in gyrA codons in Belarus and Iran were similar, therefore it is not of geographical concern for the two countries.
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